Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Metotrexat vid Erosive Inflammatory Hand Artros (MERINO)

30 oktober 2026 uppdaterad av: Ida Kristin Haugen, Diakonhjemmet Hospital

The Methotrexate in ERosive Inflammatory Osteoarthritis (MERINO) Trial: En randomiserad placebokontrollerad studie för att undersöka klinisk effekt och säkerhet av metotrexat vid erosiv inflammatorisk handartros.

A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.

Studieöversikt

Detaljerad beskrivning

The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.

Participants will be randomized 1:1 to either:

  1. Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
  2. Placebo (control group).

Both arms will receive folic acid 1mg daily.

The treatment duration for both groups is 52 weeks.

Studietyp

Interventionell

Inskrivning (Beräknad)

163

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Oslo, Norge
        • Diakonhjemmet Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
  • Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.

Exclusion Criteria:

A full list of the exclusion criteria for this study comprised the following:

  • Contraindications to methotrexate:

    • Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
    • Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
    • Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
    • Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
    • Alcohol or other drug abuse in the last year.
    • Intolerance to lactose.
  • Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.

  • Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.

  • Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.

  • Oral or intra-muscular steroids in the previous month

  • Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion

  • Analgesics or NSAIDs, unless stable dosage for ≥1 month.

  • Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.

  • Disease-modifying osteoarthritis drugs (DMOADs) previous three months.

  • Scheduled hand surgery during study participation.

  • Planning to start other treatments for hand OA in the study participation period.

  • Not able to adhere to the study visit schedule and protocol requirements.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Methotrexate

Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Methotrexate 2.5mg oral tablet.

Folic acid

Placebo-jämförare: Placebo

3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.

Additional Folic acid 1mg prescribed daily.

Placebo capsule

Folic acid

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Finger pain on a visual analogue scale
Tidsram: 6 months

Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Finger pain on a visual analogue scale
Tidsram: Month 1, 3, 9 and 12.

Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 9 and 12.
Thumb pain on a visual analogue scale
Tidsram: Month 1, 3, 6, 9 and 12.

Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain most painful finger joint on a visual analogue scale
Tidsram: Month 1, 3, 6, 9 and 12.

Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Patient-reported disease activity on a visual analogue scale
Tidsram: Month 1, 3, 6, 9 and 12.

Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Pain all joints on a visual analogue scale
Tidsram: Month 1, 3, 6, 9 and 12.

Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand diagram pain
Tidsram: Month 6.

Finger pain and thumb base pain (yes/no) on hand diagram

Month 6.
Body diagram pain
Tidsram: Month 6.

Pain in other joints (yes/no) on body diagram

Month 6.
AUSCAN
Tidsram: Month 1, 3, 6, 9 and 12.

Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
OMERACT-OARSI responder criteria
Tidsram: Month 1, 3, 6, 9 and 12.

Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria.

Month 1, 3, 6, 9 and 12.
EQ-5D
Tidsram: Month 1, 3, 6, 9 and 12.

Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome.

Month 1, 3, 6, 9 and 12.
MHOQ
Tidsram: Month 6.

Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome.

Month 6.
Grip strength
Tidsram: Month 1, 3, 6, 9 and 12.

Grip strength (in kg; using a hand dynamometer)

Month 1, 3, 6, 9 and 12.
HOOS-12
Tidsram: Month 6.

Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
KOOS-12
Tidsram: Month 6.

Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome.

Month 6.
Concomitant medication
Tidsram: Month 1, 3, 6, 9 and 12.

Concomitant medication

Month 1, 3, 6, 9 and 12.
Tender and swollen joints
Tidsram: Month 1, 3, 6, 9 and 12.

Number of tender and swollen joints (range 0-30), higher values indicate more affected joints.

Month 1, 3, 6, 9 and 12.
Physician-reported disease activity on a visual analogue scale
Tidsram: Month 1, 3, 6, 9 and 12.

Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome.

Month 1, 3, 6, 9 and 12.
Hand radiographs: Kellgren Lawrence
Tidsram: Month 6 and 12

Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Tidsram: Month 6 and 12

Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome.

Month 6 and 12
Hand radiographs: OARSI atlas
Tidsram: Month 6 and 12

Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions.

Month 6 and 12
Hand MRI
Tidsram: Month 6

MRI of dominant hand: number of joints with synovitis and BMLs

Month 6
Hand ultrasound
Tidsram: Month 1, 3, 6, 9 and 12.

Ultrasound: number of finger joints with synovial thickening and power Doppler signals.

Month 1, 3, 6, 9 and 12.
Knee ultrasound
Tidsram: Month 6

Ultrasound: degree of synovitis in knee joints

Month 6
Hip ultrasound
Tidsram: Month 6

Ultrasound: degree of synovitis in hip joints

Month 6
Adverse events
Tidsram: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

Number of adverse events, serious adverse events, and withdrawals because of adverse events.

Through study completion, maximum 12 months, in addition to 3 months after end of treatment.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sub-study: biopsy of knee OA
Tidsram: Month 6

Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients

Month 6
Sub-study: knee pain on a visual analogue scale
Tidsram: Month 6

Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.

Month 6
Question about blinding
Tidsram: Month 12

The participants are asked which treatment they think they have received

Month 12
HADS
Tidsram: Month 6

Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome.

Month 6
PCS
Tidsram: Month 6

Pain catastrophizing scale, range 0-12, higher value indicate worse outcome.

Month 6
PSQ
Tidsram: Month 6

Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome.

Month 6
Anchor questions for MCII and PASS
Tidsram: Month 6

Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires

Month 6
ASES
Tidsram: Month 6

Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome.

Month 6
Pain sensitization
Tidsram: Month 6

Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test.

Month 6
Soluble biomarkers of extracellular matrix turnover
Tidsram: Month 6 and 12

Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin).

Month 6 and 12
Omics
Tidsram: Month 6 and 12

Omics analyses of whole blood

Month 6 and 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studiestol: Tore K Kvien, MD, PhD, Professor Em.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 augusti 2021

Primärt slutförande (Faktisk)

2 september 2026

Avslutad studie (Beräknad)

1 december 2026

Studieregistreringsdatum

Först inskickad

22 september 2020

Först inskickad som uppfyllde QC-kriterierna

1 oktober 2020

Första postat (Faktisk)

8 oktober 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.

The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera